7.18.3 Clinical trials for treating bladder cancer using elemene Huang Jingqi randomly divided 230 patients with low-grade superficial uroepithelial carcinoma treated with TURBT into treatment and control groups (115 patients per group) using an Excel random number table.39 All patients underwent intra...
We describe a contemporary cohort of non-muscle invasive bladder cancer patients treated with intravesical BCG and provide benchmark outcomes data. Materials and methods: This is a retrospective review of patients receiving adequate BCG therapy at a tertiary cancer center between January 2004 and ...
Bladder cancers predominantly emerge as urothelial carcinomas with papillary tumor morphology. Lesions can be divided into 2 broad categories: non-muscle-invasive bladder cancer (NMIBC), which account for 75% of bladder cancers, and muscle-invasive bladder cancer (MIBC), which account for 25% of ...
NMIBC can be treated by removing the cancerous cells surgically, followed by a dose of chemotherapy. Radiotherapy can be an alternative treatment option, if applicable. Where there is a high chance of the condition recurring, Bacillus Calmette-Guérin (BCG) may be injected into the bladder to ...
This cohort study evaluates the use of BCG vaccine in patients with non–muscle-invasive bladder cancer who were at risk for Alzheimer disease and related
Bladder cancer is characterized by a lump or tumor that is formed in the bladder, and if aggressive, grows outside the bladder. The most common sign of urinary bladder adenocarcinoma is blood in the urine. While this symptom is not specific for cancer, you should always see your doctor if...
This type of treatment stimulates your immune system to identify and attack cancer cells. One treatment, bacillus Calmette-Guerin (BCG) therapy, sends in helpful bacteria through a catheter directly to your bladder that trigger the immune system. BCG is used for cancers that haven't spread. Anot...
Shed cells contain alpha1-oleate, treated tumors show evidence of apoptosis and the expression of cancer-related genes is inhibited (secondary endpoints). The results are especially encouraging for bladder cancer, where therapeutic failures and high recurrence rates create a great, unmet medical need....
Bladder cancer treatment remains a challenge de-spite significant improvements in preventing disease progression and improving survival. The initial clinical stage and grade remain the main determining factors of survival regardless of treatment. Superficial bladder can-cer can be treated surgically, but pa...
with the use of BCG in high-risk patients. Of concern was the finding that 35% of treated patients eventually died of bladder cancer when evaluated for many years. A recent SouthwestOncologyGroup study addressed the use of maintenance BCG. Standard induction therapy alone (6 weekly treatments) ...